Latest filingAug 28, 2026Most recent Form 4
RLAY
Relay Therapeutics, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$11.7B4 sells
Net open-market-$11.7B6 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period4transactions
- S · Open-market sells · dominant4 · 100%
Activity by reported role
A joint filing can contribute to multiple roles4transactions
- 10% owner · dominant1 · 25%
- Chief financial officer1 · 25%
- PRES1 · 25%
- SR1 · 25%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (6)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeCatinazzo ThomasCommon Stock · Direct
140,568Aug 14, 2026
Patel SanjivCommon Stock · Direct
567,699Aug 17, 2026
Sb Investment Advisers (uk) LtdCommon Stock · Indirect · See footnote
21,904,963Aug 25, 2026
Softbank Vision Fund (aiv M2) L.P.Common Stock · Indirect · See footnote
21,904,963Aug 25, 2026
SVF Pauling (Cayman) LtdCommon Stock · Indirect · See footnote
21,904,963Aug 25, 2026
Rahmer PeterCommon Stock · Direct
223,657Aug 26, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- PS-$979.9k
- CT-$349.7k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
RLAY transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| RLAY | Patel Sanjiv | PRES | sale10b5-1 | 48.1k | -$97.9M | S | −10.3% | 08/18 | 08/17 | |
| RLAY | Catinazzo Thomas | CFO | sale10b5-1 | 17.7k | -$34.9M | S | −10.3% | 08/18 | 08/14 |
Relay Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Relay Therapeutics, Inc.?
Rahmer Peter, SB INVESTMENT ADVISERS (UK) LTD, SOFTBANK VISION FUND (AIV M2) L.P., SVF Pauling (Cayman) Ltd, Patel Sanjiv, Catinazzo Thomas.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Rahmer Peter reported a sale on Aug 26, 2026 valued at $9.02M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $117,819,914.49. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.